Skip to main content
NCBI home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Feb 26;30(Suppl 1):I-25–I-30. doi: 10.1002/clc.20050

Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease

Bernard R Chaitman 1,✉, Junko Sano 1
PMCID: PMC6652839  PMID: 18373327

Abstract

Pharmacologic therapy to alleviate symptoms in chronic angina has been enhanced by the recent approval of several novel compounds that complement the traditional approach using beta‐adrenergic blocking drugs, calcium antagonists, and long‐acting nitrates. In the United States, ranolazine, a drug that inhibits late INa, was approved for patients with chronic angina that remain symptomatic on beta‐blockers, calcium antagonists, or long‐acting nitrates, on the basis of an acceptable safety profile and efficacy in several randomized placebo controlled studies. A slight increase in the QT interval is observed (<10 ms on average) at the maximum approved dose of 1,000 mg twice daily. Therefore, an ECG should be acquired at baseline and during follow‐up, and the drug should not be used in patients with QT prolongation or those who are on QT prolonging drugs unless longer term randomized outcome data demonstrates no excess risk. The MERLIN trial of non‐ST‐elevation acute coronary syndrome (NSTE ACS) randomized 6,560 patients to assess the potential benefit of ranolazine in reducing the composite endpoint of cardiovascular death, myocardial infarction, and recurrent ischemia, with results expected in 2007. In Europe, ivabradine, a drug that inhibits the hyperpolarization‐activated mixed sodium/potassium inward If current, which slows the rest and exercise heart rate, was approved in 2005. Ivabradine at a dose of 10 mg twice daily has been shown to have similar efficacy to amlodipine 10 mg once daily or atenolol 100 mg once daily in alleviating chronic angina symptoms. In this review, several other novel investigational approaches are presented and patient selection considerations for the most recent approved drugs for chronic angina are discussed. Copyright © 2007 Wiley Periodicals, Inc.

Keywords: CARISA, enhanced external counterpulsation, ERICA, ivabradine, MARISA, MERLIN, nicorandil, ranolazine, rho, spinal cord stimulation, trimetazidine

Full Text

The Full Text of this article is available as a PDF (521.8 KB).

REFERENCES

  • 1. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients with Chronic Stable Angina). 2002. Available at www.acc.org/clinical/guidelines/stable/stable.pdf. Accessibility verified December 15, 2005.
  • 2. Shea ML, Conti CR, Arora RR. An update on enhanced external counter‐pulsation. Clin Cardiol 2005; 28: 115–118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Hautvast RW, DeJongste MJ, Staal MJ, van Gilst WH, Lie KI. Spinal cord stimulation in chronic intractable angina pectoris: a randomized, controlled efficacy study. Am Heart J 1998; 136: 1114–1120. [DOI] [PubMed] [Google Scholar]
  • 4. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, et al.: for the Monotherapy Assessment of Ranolazine in Stable Angina (MARISA) Investigators. Anti‐ischemic effects and long‐term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43: 1375–1382. [DOI] [PubMed] [Google Scholar]
  • 5. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, et al.: for the Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators: Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina. JAMA 2004; 291: 309–316. [DOI] [PubMed] [Google Scholar]
  • 6. Antzelevitch C, Belardinelli L, Wu L, Fraser H, Zygmunt AC, et al.: Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004; 9: S65–S83. [DOI] [PubMed] [Google Scholar]
  • 7. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego MJ, et al.: Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110: 904–910. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/ persistent) sodium current: a potential drug target to reduce intracellular sodium‐dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 2004; 6(suppl 1): I3–I7. [Google Scholar]
  • 9. Stone PH, Gratsiansky NA, Blokhin A, Huang I, Meng L, on behalf of the ERICA Investigators. Antianginal efficacy of ranolazine when added to maximal treatment with conventional therapy: the Efficacy of Ranolazine in Chronic Angina trial. Circulation 2005; 112(suppl 2): II–748. [Google Scholar]
  • 10. Timmis A, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27: 42–48. [DOI] [PubMed] [Google Scholar]
  • 11. Chaitman BR. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials. J Cardiovasc Pharmacol Ther 2004; 9: S47–S64. [DOI] [PubMed] [Google Scholar]
  • 12. Koren MJ, Crager M, Sweeney M. Ranolazine safety and tolerability during long term treatment of stable angina. J Am Coll Cardiol 2006; 47: 218A. [DOI] [PubMed] [Google Scholar]
  • 13. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006; 113(20): 2462–2472. [DOI] [PubMed] [Google Scholar]
  • 14. Borer JS, Fox K, Jaillon P, Lerebours G, for the Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double‐blind, multicentered, placebo‐controlled trial. Circulation 2003; 107: 817–823. [DOI] [PubMed] [Google Scholar]
  • 15. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K, for the INITIATIVE Investigators. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005; 26: 2529–2536. [DOI] [PubMed] [Google Scholar]
  • 16. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, et al.: Trimetazidine European Multicenter Study Group: Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37: 279–288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Levy S. Combination therapy of Trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators. Am J Cardiol 1995; 76: 12B–16B. [PubMed] [Google Scholar]
  • 18. Szwed H, Pachocki R, Domzal‐Bochenska M, Szymczak K, Szydlowski Z, et al.: Efficacy and tolerance of Trimetazidine, a metabolic antianginal, in combination with a hemodynamic antianginal in stable exertion angina. TRIMPOL I, a multicenter study. Presse Med 2000; 29: 533–538. [PubMed] [Google Scholar]
  • 19. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, et al.: Combination treatment in stable effort angina using Trimetazidine and metoprolol: results of a randomized, double‐blind, multicenter study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001; 22: 2267–2274. [DOI] [PubMed] [Google Scholar]
  • 20. Vicari RM, Chaitman B, Keefe D, Smith WB, Chrysant SG, et al.: for the Fasudil Study Group. Efficacy and safety of fasudil in patients with stable angina: a double‐blind, placebo‐controlled, phase 2 trial. J Am Coll Cardiol 2005; 46: 1803–1811. [DOI] [PubMed] [Google Scholar]
  • 21. Chaitman BR, Ivleva AY, Ujda M, Lenis JHF, Toth C, et al.: Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. Am J Cardiol 2005; 95: 1283–1289. [DOI] [PubMed] [Google Scholar]
  • 22. MacInnes A, Fairman DA, Binding P, Rhodes JA, Wyatt MJ, et al.: The antianginal agent Trimetazidine does not exert its functional benefit via inhibition of mitochondrial long‐chain 3‐ketoacyl coenzyme a thiolase. Circ Res 2003; 93: e26–e32. [DOI] [PubMed] [Google Scholar]
  • 23. Fredj S, Sampson KJ, Liu H, Kass KS. Molecular basis of ranolazine block of LQT‐3 mutant sodium channels: evidence for site of action. Br J Pharmacol 2006; 148: 16–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Siddiqui MAA, Keam SJ. Ranolazine–a review of its use in chronic stable angina pectoris. Drugs 2006; 66: 695–712. [DOI] [PubMed] [Google Scholar]
  • 25. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, et al.: Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002; 8: 416–422. [DOI] [PubMed] [Google Scholar]
  • 26. McCormack JG, Baracos VE, Barr R, Lopaschuk GD. Effects of ranolazine on oxidative substrate preference in epitrochlearis muscle. J Appl Physiol 1996; 81: 905–910. [DOI] [PubMed] [Google Scholar]
  • 27. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005; 95: 311–316. [DOI] [PubMed] [Google Scholar]
  • 28. Morrow DA, Scirica BM, Karwatowska‐Prokopczuk E, Skene A, McCabe CH, et al.: Evaluation of a novel anti‐ischemic agent in acute coronary syndromes: design and rationale for the metabolic efficiency with ranolazine for less ischemia in non‐ST elevation acute coronary syndromes (MERLIN)–TIMI 36 Trial. Am Heart J 2006; 151: 1186e1–1186e9. [DOI] [PubMed] [Google Scholar]
  • 29. Pepine CJ, Rouleau JL, Annis K, Ducharme A, Ma P, et al.: Effects of angiotensin‐converting enzyme inhibition on transient ischemia. J Am Coll Cardiol 2003; 42: 2049–2059. [DOI] [PubMed] [Google Scholar]
  • 30. Thadani U, Strauss W, Glasser SP, Frishman W, Burger AJ, et al.: for the Nicorandil Study Group. Evaluation of antianginal and anti‐ischemic efficacy of nicorandil: results of a multicenter trial. J Am Coll Cardiol 1994; 24: 267A.8006277 [Google Scholar]
  • 31.IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil of Angina (IONA) randomized trial. Lancet 2002; 359: 1269–1275. [DOI] [PubMed] [Google Scholar]
  • 32. Ishii H, Ichimiya S, Kanashiro M, Amano T, Imai K, et al.: Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST‐segment‐elevation myocardial infarction. Circulation 2005; 112: 1284–1288. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES